A Phase 1 Randomized, Placebo-Controlled Study to Determine the Effect of LY3316531 on Capsaicin-Induced Dermal Blood Flow in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs LY-3316531 (Primary)
- Indications Psoriasis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 03 Apr 2019 Status changed from active, no longer recruiting to completed.
- 06 Mar 2019 Planned End Date changed from 4 Mar 2019 to 15 Mar 2019.
- 06 Mar 2019 Planned primary completion date changed from 4 Mar 2019 to 15 Mar 2019.